TY - JOUR
T1 - The Biology of Human Resilience
T2 - Opportunities for Enhancing Resilience Across the Life Span
AU - Feder, Adriana
AU - Fred-Torres, Sharely
AU - Southwick, Steven M.
AU - Charney, Dennis S.
N1 - Funding Information:
This work was supported by Centers for Disease Control and Prevention / National Institute for Occupational Safety and Health Grant Nos. U01-OH10729 (to AF) and U01-OH011473 (to AF) and a Brain and Behavior Research Foundation NARSAD Independent Investigator Award (to AF). We acknowledge the support from the Anne and Joel Ehrenkranz Laboratory for the Study of Human Resilience at the Icahn School of Medicine at Mount Sinai .
Funding Information:
This work was supported by Centers for Disease Control and Prevention/National Institute for Occupational Safety and Health Grant Nos. U01-OH10729 (to AF) and U01-OH011473 (to AF) and a Brain and Behavior Research Foundation NARSAD Independent Investigator Award (to AF). We acknowledge the support from the Anne and Joel Ehrenkranz Laboratory for the Study of Human Resilience at the Icahn School of Medicine at Mount Sinai. DSC is a named co-inventor on patents filed by the Icahn School of Medicine at Mount Sinai (ISMMS) relating to the treatment for treatment-resistant depression, suicidal ideation, and other disorders. ISMMS has entered into a licensing agreement with Janssen Pharmaceuticals, Inc. and it has and will receive payments from Janssen under the license agreement related to these patents for the treatment of treatment-resistant depression and suicidal ideation. Consistent with the ISMMS Faculty Handbook (the medical school policy), DSC is entitled to a portion of the payments received by the ISMMS. As SPRAVATO has received regulatory approval for treatment-resistant depression, ISMMS and thus, through the ISMMS, DSC, will be entitled to additional payments, beyond those already received, under the license agreement. DSC is a named co-inventor on several patents filed by ISMMS for a cognitive training intervention to treat depression and related psychiatric disorders. ISMMS has entered into a licensing agreement with Click Therapeutics, Inc. and has and will receive payments related to the use of this cognitive training intervention for the treatment of psychiatric disorders. In accordance with the ISMMS Faculty Handbook, DSC has received a portion of these payments and is entitled to a portion of any additional payments that the medical school might receive from this license with Click Therapeutics. DSC is a named co-inventor on a patent application filed by the ISMMS for the use of intranasally administered neuropeptide Y for the treatment of mood and anxiety disorders. This intellectual property has not been licensed. DSC and AF are named co-inventors on a patent application in the United States, and several issued patents outside the United States filed by the ISMMS related to the use of ketamine for the treatment of posttraumatic stress disorder. This intellectual property has not been licensed. SMS and DSC have received royalties from a book published by Cambridge University Press, Resilience: The Science of Mastering Life's Greatest Challenges. SF-T reports no biomedical financial interests or potential conflicts of interest.
Publisher Copyright:
© 2019 Society of Biological Psychiatry
PY - 2019/9/15
Y1 - 2019/9/15
N2 - Recent scientific and technological advances have brought us closer to being able to apply a true biopsychosocial approach to the study of resilience in humans. Decades of research have identified a range of psychosocial protective factors in the face of stress and trauma. Progress in resilience research is now advancing our understanding of the biology underlying these protective factors at multiple phenotypic levels, including stress response systems, neural circuitry function, and immune responses, in interaction with genetic factors. It is becoming clear that resilience involves active and unique biological processes that buffer the organism against the impact of stress, not simply involve a reversal of pathological mechanisms. Here, we provide an overview of recent progress in the field, highlighting key psychosocial milestones and accompanying biological changes during development, and into adulthood and old age. Continued advances in our understanding of psychological, social, and biological determinants of resilience will contribute to the development of novel interventions and help optimize the type and timing of intervention for those most at risk, resulting in a possible new framework for enhancing resilience across the life span.
AB - Recent scientific and technological advances have brought us closer to being able to apply a true biopsychosocial approach to the study of resilience in humans. Decades of research have identified a range of psychosocial protective factors in the face of stress and trauma. Progress in resilience research is now advancing our understanding of the biology underlying these protective factors at multiple phenotypic levels, including stress response systems, neural circuitry function, and immune responses, in interaction with genetic factors. It is becoming clear that resilience involves active and unique biological processes that buffer the organism against the impact of stress, not simply involve a reversal of pathological mechanisms. Here, we provide an overview of recent progress in the field, highlighting key psychosocial milestones and accompanying biological changes during development, and into adulthood and old age. Continued advances in our understanding of psychological, social, and biological determinants of resilience will contribute to the development of novel interventions and help optimize the type and timing of intervention for those most at risk, resulting in a possible new framework for enhancing resilience across the life span.
KW - Biopsychosocial
KW - Human
KW - Interventions
KW - Life span
KW - Neurobiology
KW - Resilience
UR - http://www.scopus.com/inward/record.url?scp=85070878099&partnerID=8YFLogxK
U2 - 10.1016/j.biopsych.2019.07.012
DO - 10.1016/j.biopsych.2019.07.012
M3 - Review article
C2 - 31466561
AN - SCOPUS:85070878099
SN - 0006-3223
VL - 86
SP - 443
EP - 453
JO - Biological Psychiatry
JF - Biological Psychiatry
IS - 6
ER -